// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Development of the Birmingham Lung Improvement Studies (BLISS) prognostic score for COPD patients in primary care: data from the Birmingham COPD cohort

Rachel Jordan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Diabetes

N/A

Spirometry, FeNO, and asthma control in children managed for asthma in primary care

David Lo - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Interaction with air pollution exposure for genetic loci associated with lung function

Louise Wain - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Genetic and environmental factors linked with oxidant-antioxidant balance and their relationship with respiratory health in UK Biobank

Laura Horsfall - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

ADRB2 haplotypes and risk of exacerbations in asthmatic children and young adults treated with long-acting ß2-agonists: A meta-analysis in the PiCA consortium

Leila Karimi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Polycystic ovary syndrome and lung function: a Mendelian randomization study

Diana van der Plaat - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Polycystic Ovary Syndrome

N/A

Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)

Christopher P. Denton - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

Tocilizumab

Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial

Kevin R. Flaherty - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

Kristin B. Highland - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Nintedanib

Death in ILD - Why arent we talking about it?

Anja Hudson - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial

Ganesh Raghu - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Nintedanib

Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis

Anna-Maria Hoffmann-Vold - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

N/A

Serum biomarkers in SSc-ILD: association with presence, severity and prognosis

Carmel Stock - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

CXCL12

An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease

MohammadMahdi Saeidinejad - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Oraprine

Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

Kristin B. Highland - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Nintedanib

A Combined Rheumatology/ILD Service. The Wolverhampton Experience

Ahsan Zahid - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary fibrosis

SJ8903

Interstitial lung disease associated with ANCA positivity: a retrospective analysis

Sabrina Juman - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Mycophenolate mofetil

A single center experience of rituximab for anti synthetase syndrome associated interstitial lung disease (ASS-ILD)

Amila Rathnapala - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Rituximab

Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial

Toby Maher - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Nintedanib

Late Breaking Abstract - Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD)

Toby Maher - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pirfenidone

Copyright © 2026. QuantiNova All rights reserved